Isotis Inc., an Irvine developer of bone graft substitutes, said Friday it started trading on Nasdaq.
The debut followed an exchange offer through which it bought 75% of the shares of its Lausanne, Switzerland-based parent, Isotis SA.
The company’s market value wasn’t immediately known Friday.
Isotis said it wanted to become a U.S.-traded company for several reasons, including easier access to capital and to align its listing with its primary market and operations base.
The company sells natural and synthetic substitutes for bone grafts to orthopedic and spinal surgeons. They’re used for spinal fusion, trauma repair, joint revision and surgery for head and facial fractures.
The company was formed in 2003 when Irvine-based GenSci Orthobiologics Inc. combined with Isotis SA.
